TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 9.68
(-9.95%)
TWD 9.68
(-9.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 172.23 Million TWD | 22.01% |
| 2022 | -200.36 Million TWD | -120.84% |
| 2021 | 928.34 Million TWD | 343.08% |
| 2020 | -261.8 Million TWD | -47.34% |
| 2019 | -264.94 Million TWD | -1.8% |
| 2018 | -332.24 Million TWD | -191.73% |
| 2017 | 270.7 Million TWD | 218.79% |
| 2016 | -230.73 Million TWD | 45.63% |
| 2015 | -424.71 Million TWD | -4.74% |
| 2014 | -399.72 Million TWD | 17.87% |
| 2013 | -489.86 Million TWD | -0.56% |
| 2012 | -491 Million TWD | 11.73% |
| 2011 | -193.39 Million TWD | -138.82% |
| 2010 | -422.27 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -52.47 Million TWD | -99.71% |
| 2024 Q2 | 71.36 Million TWD | 13660.25% |
| 2023 Q3 | -1.71 Million TWD | -106.66% |
| 2023 FY | - TWD | 22.01% |
| 2023 Q1 | -43.28 Million TWD | 56.46% |
| 2023 Q2 | 25.68 Million TWD | 159.34% |
| 2023 Q4 | -78.83 Million TWD | -4507.42% |
| 2022 Q3 | 20.99 Million TWD | 123.54% |
| 2022 FY | - TWD | -120.84% |
| 2022 Q1 | -20.99 Million TWD | 79.62% |
| 2022 Q2 | -89.18 Million TWD | -324.74% |
| 2022 Q4 | -99.41 Million TWD | -573.55% |
| 2021 Q4 | -103.03 Million TWD | -60.92% |
| 2021 FY | - TWD | 343.08% |
| 2021 Q2 | 1.1 Billion TWD | 3170.8% |
| 2021 Q3 | -64.02 Million TWD | -105.78% |
| 2021 Q1 | -36.09 Million TWD | 69.89% |
| 2020 Q3 | -91.92 Million TWD | 3.2% |
| 2020 Q1 | -65.58 Million TWD | 66.25% |
| 2020 Q4 | -119.86 Million TWD | -30.39% |
| 2020 FY | - TWD | -47.34% |
| 2020 Q2 | -94.97 Million TWD | -44.8% |
| 2019 Q3 | -93.32 Million TWD | -215.77% |
| 2019 Q1 | -45.68 Million TWD | 43.77% |
| 2019 Q2 | 80.61 Million TWD | 276.47% |
| 2019 Q4 | -194.32 Million TWD | -108.21% |
| 2019 FY | - TWD | -1.8% |
| 2018 Q1 | -44.52 Million TWD | 36.2% |
| 2018 Q4 | -81.24 Million TWD | -27.07% |
| 2018 Q3 | -63.93 Million TWD | -9.21% |
| 2018 Q2 | -58.54 Million TWD | -31.5% |
| 2018 FY | - TWD | -191.73% |
| 2017 FY | - TWD | 218.79% |
| 2017 Q2 | 454.51 Million TWD | 1060.11% |
| 2017 Q1 | -47.34 Million TWD | 14.91% |
| 2017 Q3 | -66.78 Million TWD | -114.69% |
| 2017 Q4 | -69.78 Million TWD | -4.48% |
| 2016 Q2 | -34.51 Million TWD | 54.7% |
| 2016 Q3 | -61.45 Million TWD | -78.05% |
| 2016 FY | - TWD | 45.63% |
| 2016 Q4 | -55.63 Million TWD | 9.47% |
| 2016 Q1 | -76.19 Million TWD | 38.56% |
| 2015 Q2 | -107.29 Million TWD | -36.91% |
| 2015 Q4 | -124.01 Million TWD | -13.46% |
| 2015 Q3 | -109.3 Million TWD | -1.87% |
| 2015 Q1 | -78.36 Million TWD | 40.63% |
| 2015 FY | - TWD | -4.74% |
| 2014 Q2 | -112.55 Million TWD | -129.94% |
| 2014 Q1 | -48.95 Million TWD | 71.14% |
| 2014 Q4 | -131.99 Million TWD | -23.82% |
| 2014 FY | - TWD | 17.87% |
| 2014 Q3 | -106.6 Million TWD | 5.28% |
| 2013 Q2 | -101.15 Million TWD | -39.75% |
| 2013 Q4 | -169.63 Million TWD | -17.89% |
| 2013 Q3 | -143.89 Million TWD | -42.24% |
| 2013 FY | - TWD | -0.56% |
| 2013 Q1 | -72.38 Million TWD | 58.37% |
| 2012 Q4 | -173.86 Million TWD | -42.85% |
| 2012 Q3 | -121.7 Million TWD | 0.0% |
| 2012 FY | - TWD | 11.73% |
| 2011 FY | - TWD | -138.82% |
| 2010 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -46.24 Million TWD | 472.438% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 393.6 Million TWD | 56.243% |
| Level Biotechnology Inc. | 98.7 Million TWD | -74.491% |
| Sagittarius Life Science Corp | -44.73 Million TWD | 484.966% |
| NeoCore Technology Co., Ltd. | -72.11 Million TWD | 338.827% |
| TaiMed Biologics Inc. | -25.23 Million TWD | 782.559% |
| GlycoNex Incorporation | -126.82 Million TWD | 235.799% |
| VBI | -6.97 Million TWD | 2570.31% |
| GeneReach Biotechnology Corp. | -143.69 Million TWD | 219.858% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 21.81 Million TWD | -689.684% |
| SynCore Biotechnology Co.,Ltd | -17.72 Million TWD | 1071.624% |
| Genomics BioSci & Tech. Co.,Ltd. | -103.61 Million TWD | 266.221% |
| Visgeneer Inc. | 973 Thousand TWD | -17600.925% |
| Mycenax Biotech Inc. | -339.48 Million TWD | 150.733% |
| Sunmax Biotechnology Co., Ltd. | 936.46 Million TWD | 81.609% |
| G&E Herbal Biotechnology Co., Ltd. | 99.83 Million TWD | -72.511% |
| Neith Corporation | -33.61 Million TWD | 612.437% |
| Medigen Vaccine Biologics Corporation | -991.09 Million TWD | 117.378% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -1.73 Million TWD | 10015.371% |
| Enimmune corporation | -228.96 Million TWD | 175.222% |
| TaiRx, Inc. | -208.64 Million TWD | 182.547% |
| CHO Pharma, Inc. | -277.73 Million TWD | 162.013% |
| EirGenix Inc. | -664.4 Million TWD | 125.922% |
| BioLASCO Taiwan Co., Ltd. | 73.9 Million TWD | -133.046% |
| Sunny Pharmtech Inc. | 69.14 Million TWD | -149.092% |
| Lin BioScience, Inc. | -1.07 Billion TWD | 116.075% |
| BioGend Therapeutics Co., Ltd. | -113.1 Million TWD | 252.273% |
| Feng Chi Biotech Corp. | 34.83 Million TWD | -394.374% |
| Bio Preventive Medicine Corp. | -62.34 Million TWD | 376.271% |
| Lukas Biomedical Inc. | -26.3 Million TWD | 754.867% |
| RBC Bioscience Corporation | 36.54 Million TWD | -371.256% |
| BiOptic Inc. | 65.03 Million TWD | -164.814% |
| BRIM Biotechnology, Inc. | -682.46 Million TWD | 125.237% |
| Shine-On BioMedical Co.,Ltd. | -33 Million TWD | 621.814% |
| Great Novel Therapeutics Biotech & Medicals | -54.91 Million TWD | 413.63% |
| Syngen Biotech Co.,Ltd. | 433.55 Million TWD | 60.275% |
| Advagene Biopharma Co., Ltd. | -80.07 Million TWD | 315.094% |
| NaviFUS Corp. | -55.79 Million TWD | 408.684% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -16.59 Million TWD | 1137.655% |
| Sinew Pharma Inc. | -163.63 Million TWD | 205.255% |
| Andros Pharmaceuticals Co.,Ltd | -61.5 Million TWD | 380.049% |
| Greenyn Biotechnology Co., Ltd | 192.4 Million TWD | 10.484% |
| Lumosa Therapeutics Co., Ltd. | -226.67 Million TWD | 175.98% |
| AP Biosciences Inc | -325.51 Million TWD | 152.91% |
| Medigen Biotechnology Corp. | -1.04 Billion TWD | 116.487% |
| 3D Global Biotech Inc. | -35.84 Million TWD | 580.472% |
| Pharmosa Biopharm Inc. | 29.13 Million TWD | -491.246% |
| Intech Biopharm Corporation | -219.58 Million TWD | 178.434% |
| Oneness Biotech Co., Ltd. | -674.22 Million TWD | 125.545% |
| Eusol Biotech Co.,Ltd. | -44.95 Million TWD | 483.151% |
| TWi Biotechnology, Inc. | -160.85 Million TWD | 207.07% |
| Ever Supreme Bio Technology Co., Ltd | 655.52 Million TWD | 73.726% |
| TCI GENE Inc. | 25.98 Million TWD | -562.908% |
| MegaPro Biomedical Co., Ltd | -110.63 Million TWD | 255.67% |
| Senhwa Biosciences, Inc. | -283.78 Million TWD | 160.69% |
| Taiwan Bio Therapeutics Co., Ltd | -145.97 Million TWD | 217.99% |
| NatureWise Biotech & Medicals Corporation | 13.85 Million TWD | -1143.538% |
| PharmaEngine, Inc. | 347.3 Million TWD | 50.41% |
| Savior Lifetec Corporation | 219.6 Million TWD | 21.573% |
| OBI Pharma, Inc. | -855.08 Million TWD | 120.142% |
| Meribank Biotech Co., Ltd | -92.56 Million TWD | 286.068% |
| Acepodia, Inc. | -764.51 Million TWD | 122.528% |
| Caliway Biopharmaceuticals Co., Ltd. | -460.09 Million TWD | 137.434% |